Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734656 · ClinicalTrials.gov registry record · NA
Pharmacogenetics of Alcohol: Treatment Implications
A NA study, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 94
- Enrollment target
NCT00734656 is a NA study that has completed, run by UConn Health. The registered enrollment target is 94 participants.
The verdict
NCT00734656, a NA study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 94 participants
- Enrollment target
Study Summary
This study will explore the hypothesis that effects of alcohol are in part mediated by increased production of neuroactive steroids, which interact with GABAA-receptors. We propose to study non-dependent drinkers using a 4-session within-subjects design in which alcohol / placebo is paired with dutasteride / placebo pretreatment. Dutasteride is a 5-alpha steroid reductase (5AR) inhibitor that limits the production of dihydrotestosterone and the 5a-reduced neuroactive steroids allopregnanolone, pregnanolone and 3a,5a-androstanediol.
Interventions
- DRUG dutasteride + ethanol
- DRUG placebo medication + ethanol
- DRUG dutasteride + placebo alcohol
- DRUG placebo medication + placebo alcohol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734656
The ClinicalTrials.gov registry entry for NCT00734656 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dutasteride + ethanol is the first listed.
NCT00734656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734656 about?
NCT00734656 is a clinical study titled "Pharmacogenetics of Alcohol: Treatment Implications". This study will explore the hypothesis that effects of alcohol are in part mediated by increased production of neuroactive steroids, which interact with GABAA-receptors. We propose to study non-dependent drinkers using a 4-session within-subjects design in which alcohol / placebo is paired with duta...
What is the current status of trial NCT00734656?
This trial is currently completed. It is a NA study. The enrollment target is 94 participants. The study started on 2007-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00734656?
The interventions under investigation include: dutasteride + ethanol (DRUG), placebo medication + ethanol (DRUG), dutasteride + placebo alcohol (DRUG), placebo medication + placebo alcohol (DRUG).
Who is sponsoring clinical trial NCT00734656?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.